belatacept

Ligand id: 6892

Name: belatacept

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: belatacept

No information available.
Summary of Clinical Use
Approved for prophylaxis of organ rejection after kidney transplant.
The first analysis of long-term outcomes (7 years post-transplant) for belatacept-induced immunosuppression compared to cyclosporine treatment are reported by Vincenti et al. (2016) [2]. These results, from clinical trial NCT00256750, show a clear and significant benefit from treating with belatacept rather than cyclosporine. The authors suggest that the improvement is likely due to the alternative mechanism of action of belatacept (blocks T-cell costimulation) and its non-nephrotoxic nature, in comparison to cyclosporine which is often the cause of failure of transplanted kidneys over time.
Mechanism Of Action and Pharmacodynamic Effects
Binding of belatacept to CD80/86 (on antigen presenting cells) provides a negative feedback mechanism which results in T-cell deactivation and immunosuppression.
External links